Opiant Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company primarily engaged in developing medicines for addiction treatment and drug overdose reversal. Founded in 2005 and headquartered in Richmond, Virginia, Opiant's core products and services include NARCAN (naloxone hydrochloride) Nasal Spray, a life-saving opioid overdose reversal treatment licensed to Adapt Pharma and subsequently marketed by Emergent BioSolutions. The company's product pipeline encompasses OPNT003, a nasal nalmefene formulation for opioid overdose reversal designed to address powerful synthetic opioids like fentanyl; nasal naltrexone for alcohol use disorder treatment; and OPNT004, an injectable cannabinoid CB-1 receptor antagonist (drinabant) targeting acute cannabinoid overdose. Opiant also engages in developing additional therapeutics focused on addiction and overdose conditions. Recent strategic developments include its acquisition by Indivior PLC in March 2023, which expanded Indivior's addiction treatment portfolio and leveraged Opiant's late-stage assets and pipeline advancement. Opiant has entered partnerships such as the licensing agreement with Sanofi for drinabant development and a collaboration with Aptar Pharma for innovative nasal drug delivery systems. These initiatives position Opiant and its parent company Indivior to strengthen their offerings across the continuum from overdose rescue to recovery within the U.S. and global markets. The company operates primarily in the specialty pharmaceutical and biotechnology sector with a focus on addiction medicine solutions.
What's The Opiant CVR Worth?
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD
Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript
Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript
Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
Why Opiant Pharmaceuticals Shares Are Soaring Today
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript
Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022
Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program
Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2021 Results - Earnings Call Transcript
Opiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference
Opiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
Opiant Pharmaceuticals to Participate in September Investor Conferences
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2021 Results - Earnings Call Transcript
Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)